Number of Positive Lymph Nodes and Survival in Endometrial Carcinoma: A Proposal for a Modified Staging
Lianwei Li,Mengsi Zhang,Chao Na
DOI: https://doi.org/10.2147/ijwh.s438064
2024-01-21
International Journal of Women s Health
Abstract:Lianwei Li, 1 Mengsi Zhang, 2 Chao Na 3 1 Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, People's Republic of China; 2 Medical Record Statistics Department, The Second Hospital of Heilongjiang Province, Harbin, Heilongjiang, 150028, People's Republic of China; 3 Integrated Traditional Chinese and Western Medicine Rehabilitation Medical Center, Heilongjiang Provincial hospital, Harbin, Heilongjiang, 150036, People's Republic of China Correspondence: Chao Na, Integrated Traditional Chinese and Western Medicine Rehabilitation Medical Center, Heilongjiang Provincial Hospital, No. 82 Zhongshan Road, Xiangfang District, Harbin, Heilongjiang, 150036, People's Republic of China, Tel +86-13313619817, Email Purpose: To construct a new clinical staging system including the number of lymph node metastases to supplement the International Federation of Gynecology and Obstetrics (FIGO) staging for the prognosis of endometrial carcinoma patients. Methods: This cohort study retrieved the data of 28,824 patients confirmed as endometrial carcinoma between 2010 and 2015 in the surveillance, epidemiology, and end results (SEER) database. COX risk proportional model was established to evaluate the association between FIGO staging with the all-cause mortality of endometrial carcinoma. The diagnostic value of FIGO staging and the new staging for the mortality of patients were evaluated by receiver operator characteristic curve (ROC). Hazard ratio (HR) and 95% confidence interval (CI) were effect size. Results: The 5-year survival rate of all participants was 77.21%. The median follow-up time was 60.00 (60.00,60.00) months. Patients at FIGO staging IB (HR=1.75, 95% CI: 1.62– 1.90), FIGO staging II (HR=2.22, 95% CI: 2.00– 2.47), FIGO staging IIIA (HR=2.74, 95% CI: 2.43– 3.09), FIGO staging IIIB (HR=4.07, 95% CI: 3.48– 4.76), FIGO staging IIIC1 (HR=3.84, 95% CI: 3.52– 4.20), FIGO staging IIIC2 (HR=4.52, 95% CI: 4.09– 4.99), FIGO staging IVA (HR=5.56, 95% CI: 4.58– 6.74), and FIGO staging IVB (HR=7.62, 95% CI: 6.94– 8.36) were associated with increased risk of all-cause mortality of endometrial carcinoma patients. After adding positive lymph nodes as another covariate in Model 3, the effect on of FIGO staging survival was reduced when the FIGO staging was higher than stage III/IV. The C-index of the new staging 0.781 (95% CI: 0.774– 0.787) was higher than FIGO staging 0.776 (95% CI: 0.770– 0.783). Conclusion: Our new staging using the number of positive lymph nodes supplement to the FIGO staging was superior than the FIGO staging for predicting the prognosis of endometrial cancer patients, which might help more accurately identify endometrial carcinoma patients who were at high risk of mortality and offer timely treatments in these patients. Keywords: positive lymph nodes, FIGO staging, endometrial cancer, prediction Endometrial carcinoma is a type of epithelial malignancy that arises from the endometrium, which ranks among the most prevalent gynecological malignancies. 1 According to the epidemiological survey, the number of new cases of endometrial carcinoma exceeded 410,000 globally in 2020, making endometrial carcinoma the sixth most common cancer among women, and the morbidity and mortality of endometrial carcinoma are both on the rise. 2–4 To identify more reliable biomarkers related to the prognosis of endometrial carcinoma patients was necessary. Previous evidence suggested that lymph node involvement is an important factor affecting the survival of endometrial carcinoma patients. 5 The 5-year survival rate of endometrial carcinoma patients is more than 80% for those without lymph node metastasis, but only about 60% for those with lymph node metastasis. 6,7 Currently, the International Federation of Obstetrics and Gynecology (FIGO) and the American Joint Committee on Cancer (AJCC) staging systems are the main tools for assessing the prognosis of endometrial carcinoma, and both staging systems assess lymph node involvement based on the site of lymph node metastasis (pelvic/para-aortic). 8,9 In addition to the site of lymph node metastasis, the number of lymph node metastases is also a vital index to assess the prognosis of endometrial carcinoma patients. 10 A previous study revealed that the survival of patients with FIGO IIIC1 endometrial carcinoma with multiple lymph node metastases was significantly worse than patients with only one lymph node metastasis. 11 There was evidence indicated that the number of positive lymph nodes is an important supplement of AJCC stage for improving the accuracy of evaluation and prognosis stratification for breast cancer, gastri -Abstract Truncated-
obstetrics & gynecology